Copy to clipboard 
CONMED reported 3Q25 orthopedic sales of $138.2 million, up 5.9% compared to the third quarter of 2024. For the first nine months of the year, the company generated $417.2 million in orthopedic sales, up 3% compared to the prior period.
Supply constraints for orthopedic products has been an ongoing headwind for the company, but CONMED made progress throughout 2025 and notched record manufacturing volumes in the third quarter with record reduction of backlogged critical SKUs. Company leadership stopped short of declaring victory, but said they were in the later innings of dealing with the supply headwinds.
BioBrace is developing into the cornerstone of the company’s sports medicine offense and is now used in 70 different procedure types, from rotator cuff and ACL repairs to Achilles and gluteus medius reconstructions, underscoring its versatility and clinical relevance.
“The beauty of BioBrace is it has a clinical indication where tissue weakness exists, it’s approved to be used, and it has the clinical benefit of strength and healing, which allows for surgeons to continue to expand and use it in extended indications where they haven’t been normally able to use it with other products on the market. And that’s just the expansion from the 50s to the 60s to 70s is just a natural evolution of time where surgeons continue to see clinical application for it,” said CONMED CEO Pat Beyer.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $12.6 | $11.7 | $0.9 | 7.5% |
| Sports Medicine | $125.6 | $118.8 | $6.8 | 5.7% |
| Total | $138.2 | $130.5 | $7.7 | 5.9% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $38.0 | $34.7 | $3.3 | 9.5% |
| Sports Medicine | $379.2 | $370.3 | $8.9 | 2.4% |
| Total | $417.2 | $405.0 | $12.2 | 3% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $52.5 | $49.7 | $2.8 | 5.6% |
| OUS | $85.7 | $80.8 | $4.9 | 6.1% |
| EMEA | $30.9 | $28.8 | $2.1 | 7.4% |
| APAC | $33.8 | $32.8 | $0.9 | 2.9% |
| ROW | $21.0 | $19.2 | $1.8 | 9.5% |
| Total | $138.2 | $130.5 | $7.7 | 5.9% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $156.7 | $156.0 | $0.7 | 0.5% |
| OUS | $260.5 | $249.0 | $11.5 | 4.6% |
| EMEA | $102.5 | $97.0 | $5.5 | 5.6% |
| APAC | $92.5 | $90.3 | $2.2 | 2.4% |
| ROW | $65.6 | $61.7 | $3.9 | 6.3% |
| Total | $417.2 | $405.0 | $12.2 | 3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $337.9 | |
| Cost of Sales | $171.8 | 50.8% |
| Selling and Admin | $140.3 | 41.5% |
| R&D | $13.9 | 4.1% |
| Other | $9.0 | 2.7% |
| Net Earnings | $2.9 | 0.8% |
CONMED reported 3Q25 orthopedic sales of $138.2 million, up 5.9% compared to the third quarter of 2024. For the first nine months of the year, the company generated $417.2 million in orthopedic sales, up 3% compared to the prior period.
Supply constraints for orthopedic products has been an ongoing headwind for the company, but CONMED made...
CONMED reported 3Q25 orthopedic sales of $138.2 million, up 5.9% compared to the third quarter of 2024. For the first nine months of the year, the company generated $417.2 million in orthopedic sales, up 3% compared to the prior period.
Supply constraints for orthopedic products has been an ongoing headwind for the company, but CONMED made progress throughout 2025 and notched record manufacturing volumes in the third quarter with record reduction of backlogged critical SKUs. Company leadership stopped short of declaring victory, but said they were in the later innings of dealing with the supply headwinds.
BioBrace is developing into the cornerstone of the company’s sports medicine offense and is now used in 70 different procedure types, from rotator cuff and ACL repairs to Achilles and gluteus medius reconstructions, underscoring its versatility and clinical relevance.
“The beauty of BioBrace is it has a clinical indication where tissue weakness exists, it’s approved to be used, and it has the clinical benefit of strength and healing, which allows for surgeons to continue to expand and use it in extended indications where they haven’t been normally able to use it with other products on the market. And that’s just the expansion from the 50s to the 60s to 70s is just a natural evolution of time where surgeons continue to see clinical application for it,” said CONMED CEO Pat Beyer.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $12.6 | $11.7 | $0.9 | 7.5% |
| Sports Medicine | $125.6 | $118.8 | $6.8 | 5.7% |
| Total | $138.2 | $130.5 | $7.7 | 5.9% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $38.0 | $34.7 | $3.3 | 9.5% |
| Sports Medicine | $379.2 | $370.3 | $8.9 | 2.4% |
| Total | $417.2 | $405.0 | $12.2 | 3% |
Orthopedic Sales by Geography
| Region | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $52.5 | $49.7 | $2.8 | 5.6% |
| OUS | $85.7 | $80.8 | $4.9 | 6.1% |
| EMEA | $30.9 | $28.8 | $2.1 | 7.4% |
| APAC | $33.8 | $32.8 | $0.9 | 2.9% |
| ROW | $21.0 | $19.2 | $1.8 | 9.5% |
| Total | $138.2 | $130.5 | $7.7 | 5.9% |
| Region | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $156.7 | $156.0 | $0.7 | 0.5% |
| OUS | $260.5 | $249.0 | $11.5 | 4.6% |
| EMEA | $102.5 | $97.0 | $5.5 | 5.6% |
| APAC | $92.5 | $90.3 | $2.2 | 2.4% |
| ROW | $65.6 | $61.7 | $3.9 | 6.3% |
| Total | $417.2 | $405.0 | $12.2 | 3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $337.9 | |
| Cost of Sales | $171.8 | 50.8% |
| Selling and Admin | $140.3 | 41.5% |
| R&D | $13.9 | 4.1% |
| Other | $9.0 | 2.7% |
| Net Earnings | $2.9 | 0.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
